INTRODUCTION
============

The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved protein kinase that is critical for homeostatic control of cell growth and metabolism (reviewed in [@B38]; [@B45]; [@B49]). mTOR functions within two distinct complexes, TORC1 and TORC2 ([@B50]). Although most organisms have a single *TOR* gene, some yeast, including *Saccharomyces cerevisiae*, have two, *TOR1* and *TOR2*. In yeast, TORC1 consists of four proteins: Tor1 or Tor2, Kog1 (homologue of Raptor), Lst8 (homologue of mLST8/GβL), and Tco89. TORC1 responds to nutritional status and positively regulates protein synthesis and cell growth while negatively regulating autophagy (reviewed in [@B49]).

TORC1 resides predominantly on the vacuole membrane in yeast ([@B66]; [@B1]; [@B75]; [@B74]; [@B4]). The localization and activity of TORC1 on the vacuole is critical for yeast viability. Moreover, several vacuole-related mutants are synthetically lethal with the *tor1Δ* mutant, which retains some TORC1 function ([@B85]). Mammalian TORC1 is recruited to late endosomes and lysosomes in response to the presence of amino acids ([@B70]). This localization is critical for TORC1 function ([@B69]; [@B84]). However, the mechanisms that localize TORC1 to the yeast vacuole and the mammalian lysosome are not known.

Some key regulators of TORC1 are also localized on the yeast vacuole and mammalian lysosome. These include the yeast EGO complex---in mammalian cells termed Ragulator ([@B19]; [@B25]; [@B4]; [@B42]; [@B69])---and the mammalian lysosomal V-ATPase ([@B84]).

Phosphatidylinositol 3,5-bisphosphate (PI(3,5)P~2~), a crucial, low-abundance signaling phospholipid found in the endomembrane system, is generated from phosphatidylinositol 3-phosphate (PI3P) by the lipid kinase Fab1/PIKfyve (reviewed in [@B17]; [@B54]). Fab1/PIKfyve is the sole enzyme that generates PI(3,5)P~2~ ([@B27]; [@B83]). In yeast, Fab1 is positively regulated by Vac7 ([@B6]; [@B26]), which has no known mammalian homologue. In addition, Fab1 activity requires the conserved scaffolding protein Vac14 ([@B7]; [@B36]; [@B71]). PI(3,5)P~2~ is converted to PI3P by the conserved lipid phosphatase Fig4 ([@B26]; [@B67]), which paradoxically also serves as a positive regulator of Fab1 ([@B21]).

Mutations predicted to cause only minor changes in PI(3,5)P~2~ levels are associated with severe neurological diseases ([@B13], [@B14]). Moreover, loss of human Fig4 results in a multisystem congenital disorder that leads to infant mortality ([@B11]). Yet, despite its importance in human physiology, only a fraction of the processes regulated by PI(3,5)P~2~ have been identified. Moreover, few proteins that bind directly to PI(3,5)P~2~ have been identified, and there are no known motifs that predict an interaction with PI(3,5)P~2~.

Recent studies revealed that the WD-40 domain of mammalian Raptor binds PI(3,5)P~2~ in vitro ([@B8]), which raised the intriguing possibility that PI(3,5)P~2~ is an upstream regulator of TORC1. Consistent with this hypothesis, knockdown of PIKfyve, Vac14, or Fig4 in adipocytes resulted in a loss of the ability of insulin to stimulate TORC1 phosphorylation of S6 kinase (S6K). However, in these prior studies the conditions used to knock down Fig4 and Vac14 did not have a significant effect on PI(3,5)P~2~ levels, and knockdown of PIKfyve had a modest effect. Thus how the short hairpin RNA experiments affected TORC1 function is unclear. Furthermore, in stimulated adipocytes, TORC1 was found at the plasma membrane, raising questions about the subcellular location where PI(3,5)P~2~ activates TORC1. In addition, the effect of PI(3,5)P~2~ on general pathways regulated by TORC1 was not assessed.

Here we report that PI(3,5)P~2~ is a positive regulator of TORC1 activity on the yeast vacuole. We find that the TORC1 substrate Sch9, a yeast homologue of S6K, localizes on the vacuole via direct binding to PI(3,5)P~2~ and that this localization is required for TORC1-dependent phosphorylation of Sch9. Moreover, we find that PI(3,5)P~2~ regulates TORC1 phosphorylation of multiple targets and regulates multiple TORC1 functions. We show that PI(3,5)P~2~ promotes nutrient-regulated endocytosis from the plasma membrane and inhibits autophagy via a requirement for PI(3,5)P~2~ in TORC1-dependent phosphorylation of Npr1 and Atg13, respectively. Moreover, the requirement of PI(3,5)P~2~ in TORC1 inhibition of autophagy is exacerbated by a TORC1-independent role for PI(3,5)P~2~ in the degradation of autophagic bodies. Thus, under nutrient-rich conditions, mutants with defects in PI(3,5)P~2~ carry a load of autophagic bodies in the vacuole. Together these findings show that PI(3,5)P~2~ is a conserved upstream regulator of TORC1 and suggest that PI(3,5)P~2~ provides a platform for TORC1 signaling from the vacuole/lysosome. Moreover, these studies show that PI(3,5)P~2~ is a key regulator of cellular response to nutrient status via modulation of TORC1.

RESULTS
=======

PI(3,5)P~2~ is required for TORC1 activity in vivo
--------------------------------------------------

Inhibition of PIKfyve causes a defect in insulin-dependent activation of mTORC1 in L1-3T3 adipocytes ([@B8]). To determine whether PI(3,5)P~2~ is a conserved, general regulator of TORC1, we tested whether PI(3,5)P~2~ plays a role in TORC1 activation in yeast. Yeast mutants with defects in TORC1 activity are hypersensitive to the TORC1 inhibitor rapamycin ([@B31]; [@B50]). Thus we tested growth on 1 ng/ml rapamycin, which is sublethal for wild-type yeast. Mutants with impaired TORC1 function, *tor1Δ* and *gtr1Δ*, exhibit hypersensitivity to rapamycin ([Figure 1A](#F1){ref-type="fig"}; [@B4]). Similarly, *vac14Δ*, *vac7Δ*, and *fab1Δ* mutants, which contain little or no detectable PI(3,5)P~2~, respectively ([@B6]; [@B26]; [@B20]), also exhibited hypersensitivity to rapamycin ([Figure 1A](#F1){ref-type="fig"}). To further address the hypothesis that PI(3,5)P~2~ regulates TORC1 activity, we tested whether the hyperactive, dominant *FAB1^VLA^* mutant suppressed the rapamycin hypersensitivity of the *vac7Δ* and *vac14Δ* mutants. Expression of an additional copy of Fab1 from a low-copy plasmid in the *vac7Δ* mutant had little effect on the levels of PI(3,5)P~2~ ([@B21]) or on the suppression of the sensitivity of *vac7Δ* to rapamycin ([Figure 1B](#F1){ref-type="fig"}). In contrast, expression of the hyperactive *FAB1^VLA^* mutant in *vac7Δ* or *vac14Δ* yeast, which raises the levels of PI(3,5)P~2~ above levels found in wild-type cells by ∼1.5- and 3-fold, respectively ([@B21]), suppressed the sensitivity of the *vac7Δ* and *vac14Δ* mutants to rapamycin ([Figure 1B](#F1){ref-type="fig"}). This finding strongly suggests that PI(3,5)P~2~ levels rather than the Vac7 or Vac14 protein per se are required for TORC1 function. Moreover, in the *vac7Δ* mutant, whereas PI(3,5)P~2~ levels are deeply lowered, PI3P levels are twofold higher, yet this elevation in PI3P does not rescue TORC1 function; furthermore, both phosphatidylinositol 4-phosphate (PI4P) and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P~2~) levels are similar to wild-type levels ([@B26]). Similarly, in the *vac14Δ* mutant, only PI(3,5)P~2~ levels are lowered. In this mutant, PI3P levels are elevated above wild-type levels by 20%, whereas PI4P and PI(4,5P)~2~ levels are similar to wild-type levels ([@B18]). Together these studies strongly suggest that PI(3,5)P~2~ modulates TORC1 function.

![PI(3,5)P~2~ is required for TORC1 activity. (A) The *fab1Δ*, *vac7Δ*, and *vac14Δ* mutants are hypersensitive to rapamycin. The indicated strains were grown to mid log phase in YEPD medium and then diluted onto SC plates containing DMSO (control) or 1 ng/ml rapamycin, a sublethal dose for wild-type yeast. *tor1Δ* and *gtr1Δ* mutants have known defects in TORC1 function. Correlation between the ability to grow in the presence of 1 ng/ml rapamycin and intracellular PI(3,5)P~2~ levels was indicated by *fab1Δ* mutants, which have no detectable PI(3,5)P~2~, *vac7Δ* cells with very low levels of PI(3,5)P~2~, and *vac14Δ* cells with more PI(3,5)P~2~ than *vac7Δ*. (B) Increasing PI(3,5)P~2~ in *vac7Δ* or *vac14Δ* mutants restores TORC1 activity. Sensitivity of *vac7Δ* or *vac14Δ* mutants to 1 ng/ml rapamycin is rescued by elevation of PI(3,5)P~2~ levels. Wild-type yeast and *vac7Δ* or *vac14Δ* mutants with plasmids expressing Fab1 or dominant active *FAB1^VLA^* were grown to mid log phase in SC-Ura medium and then diluted onto SC-Ura plates containing DMSO (control) or 1 ng/ml rapamycin.](1171fig1){#F1}

PI(3,5)P~2~ activates TORC1 on the vacuole
------------------------------------------

Mammalian Raptor binds PI(3,5)P~2~, in vitro ([@B8]), and thus we tested whether Kog1, the yeast homologue of Raptor, binds to PI(3,5)P~2~. A construct encoding glutathione *S*-transferase (GST) fused to amino acids 1162--1557 of Kog1, which contains the WD-40 domain, was used for expression and purification of the protein from *Escherichia coli.* We found that Kog1(1162--1557) bound PI(3,5)P~2~ with a dissociation constant of 19 ± 6 μM (Supplemental Figure S1). These data suggested the possibility that PI(3,5)P~2~ plays a role in the activation of TORC1 via its association with Kog1. Note that this affinity is substantially lower than that observed for Atg18, which exhibits a dissociation constant of \<0.2 μM ([Table 1](#T1){ref-type="table"}; [@B16]). However, the affinity of Atg18 for PI(3,5)P~2~ is exceptionally strong, likely due to two adjacent phosphoinositide-binding sites ([@B2]; [@B43]; [@B78]). Of importance, dissociation constants of 20 μM are commonly observed in biologically significant interactions.

###### 

Surface plasmon resonance analysis of Kog1- or Sch9-binding affinity for PI(3,5)P~2~.

                                                       *K*~d~ (μM)   SEM (*K*~d~)   *R*~max~   SEM (*R*~max~)   *R*^2^
  ---------------------------------------------------- ------------- -------------- ---------- ---------------- --------
  A. Kog1- and Sch9-binding affinity for PI(3,5)P~2~                                                            
  Kog1                                                 19            6              1627       206              0.8
  Sch9                                                 11            2              2743       154              0.96
  B. Atg18-binding affinity for PI(3,5)P~2~                                                                     
  i                                                    0.046         0.010          5053       332              0.8
  ii                                                   0.076         0.015          4341       217              0.89

Data are representative of three experiments. i, ii: SPR analysis of Atg18- and PI(3,5)P~2~-binding affinity performed alongside the Kog1 peptide ([Figure 2](#F2){ref-type="fig"}) or Sch9 peptide ([Figure 3](#F3){ref-type="fig"}), respectively.

Phosphorylated phosphoinositide lipids often function by recruiting downstream effectors to specific membrane subdomains. The translocation of mTORC1 onto the lysosome is important for mTORC1 activation under amino acid stimulation in mammalian cells ([@B69]). This raised the possibility that PI(3,5)P~2~ regulates yeast TORC1 function in part by recruiting TORC1, especially Kog1, to the vacuole or a subdomain on the vacuole.

Using fluorescence microscopy ([Figure 2, A and B](#F2){ref-type="fig"}), as well as cell fractionation ([Figure 2, C and D](#F2){ref-type="fig"}), we probed the effect of PI(3,5)P~2~ on the localization of Tor1--3x green fluorescent protein (GFP) and Kog1-3xGFP. However, by cell fractionation, we did not detect large differences in the localization of Tor1-3xGFP or Kog1-3xGFP in the *vac7∆* strain. Note that these tagged proteins were functional as measured by rapamycin sensitivity (Supplemental Figure S2, A and B). Similarly, the localization of Tor1-3xGFP(D330) and Kog1-3xGFP was largely unaffected by expression of the hyperactive *FAB1^VLA^* mutant (Supplemental Figure S2, C--G). In addition, the association of Kog1 with Tor1 was similar in wild type and the *vac7Δ* mutant (Supplemental Figure S2H). Nonetheless, we hypothesized that a small difference in localization of Kog1, and hence TORC1 to the vacuole, might result in a significant defect in TORC1 activity. Accordingly, we undertook a second approach to monitor the effect of PI(3,5)P~2~ on Kog1 localization.

![PI(3,5)P~2~ is required for TORC1 activity on the vacuole, but TORC1 remains on the vacuole in mutants with low levels of PI(3,5)P~2~. (A) 3xGFP(D330)-Tor1 (green) and (B) Kog1-3xGFP (green) localizes on the vacuole membrane (red) in wild-type and *vac7Δ* mutant yeast. Vacuole membranes were visualized with FM 4-64. (C, D) In either the presence or absence of PI(3,5)P~2~, 3xGFP(D330)-Tor1 or Kog1-3xGFP is in the pellet (P) fraction, which includes vacuole membranes. Cell lysates of the indicated strains were centrifuged at 13,000 × *g* for 10 min at 4°C. Supernatant (S) fractions and whole-cell lysates (W) were suspended in the same volume of sample buffer, and pellet (P) fractions were suspended in twice the volume of sample buffer. Loading control for cell fractionation: Vac7 and Vac8, which tightly localize on the vacuole membrane. Red asterisk, Vac7 protein. (E) More Vac8-Kog1-GFP (green) localizes on the vacuole membrane (red, FM 4-64) than Kog1-GFP. Note that both Vac8-Kog1-GFP and Kog1-GFP are overexpressed, which likely accounts for the partial cytoplasmic localization of Kog1-GFP. (F) Expression of the Vac8-Kog1 fusion protein partially suppressed the rapamycin sensitivity of *vac14Δ* mutants at 37°C. The *vac14Δ* mutants with plasmids expressing empty vector (mock), Kog1, Vac8-Kog1, or Vac14 were grown to mid log phase in SC-URA medium and then diluted onto SC-URA plates containing DMSO (control) or 0.25 ng/ml rapamycin. Note that this level of rapamycin does not interfere with growth of the *vac14Δ* mutant at 24°C for 7 d. (G) In the *vac14Δ* mutant, Vac8-Kog1 cofractionates with the P13 fraction at either 24 or 37°C (30 min), which includes the vacuole. Cell lysates were centrifuged at 13,000 × *g* for 10 min at 4°C. Supernatant (S) fractions and whole-cell lysates (W) were resuspended in the same volume of sample buffer, and the pellet (P) fractions were resuspended in twice the volume of sample buffer. Loading controls for cellular fractionation: Vac7 and Vac8, which tightly localize on the vacuole membrane. Red asterisk, Vac7 protein.](1171fig2){#F2}

We tested and found that artificially tethering Kog1 to the vacuole partially suppresses the rapamycin hypersensitivity of the *vac14Δ* mutant. Vac8, a vacuolar membrane protein ([@B77]), does not require PI(3,5)P~2~ for its localization to the vacuole. Thus we used Vac8 as a PI(3,5)P~2~-independent tether. In contrast to Kog1-GFP, which displayed some diffuse cytosolic staining pattern in the *vac14∆* strain, we found that the Vac8-Kog1 fusion protein showed better colocalization on the vacuole membrane in the *vac14Δ* mutant ([Figure 2E](#F2){ref-type="fig"}). Vac8-Kog1 partially suppressed the rapamycin hypersensitivity of the *vac14Δ* mutant ([Figure 2F](#F2){ref-type="fig"}). Note that the partial rescue by Vac8-Kog1 was not due to changes in the amount of Kog1, as the levels of the two proteins were similar at both 24 and 37°C ([Figure 2G](#F2){ref-type="fig"}). Similarly, although Kog1 was distributed between the pellet and supernatant fractions of cell lysates at 24 and 37°C, Vac8-Kog1 was found primarily in the P13 membrane fraction, which includes the vacuole ([Figure 2G](#F2){ref-type="fig"}); the integral membrane proteins Vac7 and Vac8 were also localized to the P13 fraction. These data strongly support the hypothesis that at least one role of PI(3,5)P~2~ in TORC1 function occurs on the vacuole membrane. Furthermore, these data link the rapamycin hypersensitivity of the *vac14Δ* mutant to defects in both TORC1 localization and function.

The TORC1 substrate Sch9 localizes on the vacuole via PI(3,5)P~2~
-----------------------------------------------------------------

To test for additional roles for PI(3,5)P~2~, we investigated whether PI(3,5)P~2~ recruits a subset of TORC1 substrates onto the vacuole membrane. Accordingly, we examined a well-characterized direct target of TORC1, Sch9, which is partially localized on the vacuole ([@B75]). Yeast Sch9 shares similar functions with mammalian S6 kinase, a downstream target and effector of mTORC1.

We first tested whether TORC1-dependent phosphorylation of Sch9 requires PI(3,5)P~2~. We used Sch9^T570A^, which contains five sites in its C-terminus that are directly phosphorylated by TORC1 and is missing a TORC1-independent phosphorylation site ([@B75]). On 6% SDS--PAGE gel, Sch9^T570A^-HA~5~ migrates as multiple bands. The upper bands are due to phosphorylation; treatment with λ-phosphatase selectively removed the upper-migrating species (Supplemental Figure S3A). Examination of these proteins on 15% SDS--PAGE gel indicated that there was no apparent difference in stability of the phosphorylated versus nonphosphorylated forms of the protein (Supplemental Figure S3A).

Previous studies using a chemical fragmentation assay showed that phosphorylation of Sch9^T570A^-HA~5~ is dependent on TORC1 activity, as measured by loss of phosphorylation in cells treated with rapamycin ([@B75]). Furthermore, phosphorylation of Sch9^T570A^-HA~5~ is virtually absent in a *gtr1Δ* mutant ([@B4]). Consistent with these studies, the gel shift assay also indicated that phosphorylation of Sch9^T570A^-HA~5~ was blocked by addition of rapamycin and required the presence of Gtr1 (Supplemental Figure S3A). Of note, Sch9^T570A^-HA~5~ was significantly less phosphorylated in the *fab1Δ* and *vac7Δ* mutants ([Figure 3A](#F3){ref-type="fig"}). These findings demonstrate that mutants that do not maintain normal levels of PI(3,5)P~2~ are defective in TORC1-dependent phosphorylation of Sch9.

![PI(3,5)P~2~ is required for the localization of Sch9 on the vacuole. (A) Phosphatase treatment indicates that phosphorylation of Sch9-T570A-HA can be assayed by altered mobility on 6% SDS--PAGE. Lysates from 5 × 10^6^ cells from a wild-type strain transformed with a plasmid expressing Sch9-T570A-HA~5~ were incubated at 30°C for 1 h with (+) or without (--) 6000 U of λ-phosphatase (New England Biolabs, Ipswich, MA). As assessed by mobility on 6% SDS--PAGE, the degree of TORC1-dependent phosphorylation of Sch9-T570A-HA~5~ is greatly diminished in the *gtr1Δ* mutant. The degree of TORC1-dependent phosphorylation of Sch9-T570A-HA~5~ is also greatly diminished in *fab1Δ* and *vac7Δ* mutants. (B) TORC1-dependent phosphorylation of Sch9-T570A-HA~5~ in *vac7Δ* and *vac14Δ* mutants is rescued by elevation of PI(3,5)P~2~ levels. TORC1-dependent phosphorylation of Sch9-T570A-HA~5~ assessed by mobility on 6% SDS--PAGE in wild-type, *vac7Δ*, or *vac14Δ* cells with a vector control or plasmids expressing Fab1 or *FAB1^VLA^*. In A and B, loading controls were Sch9-T570A-HA~5~ and Pgk1 run on 15% SDS--PAGE. (C) GFP-Sch9 (green) partially colocalizes with the vacuole membrane (red) in wild-type and *gtr1Δ* yeast but not in the *vac7Δ* mutant. Vacuole membranes were visualized with FM 4-64. (D) Increasing PI(3,5)P~2~ restores the localization of GFP-Sch9 in *vac7Δ* mutants. Mock or *FAB1^VLA^* plasmids were expressed in wild-type or *vac7Δ* cells. Analysis of degree of colocalization of GFP-Sch9 and FM 4-64 is shown in Supplemental Figure S3, B and C. (E) Schematic of Sch9 indicating the peptide (aa 1--400) tested for binding to PI(3,5)P~2~, the predicted calcium/lipid-binding C2 domain (aa 182*--*356), and the kinase domain (aa 400--824). (F) Recombinant GST-Sch9 fusion protein was tested for its ability to bind PI(3,5)P~2~, using surface plasmon resonance. The peptide including the C2 domain of Sch9 binds PI(3,5)P~2~ with a dissociation constant of 11 ± 2 μM ([Table 1](#T1){ref-type="table"}). Equilibrium-state response levels (RU) for each protein concentration were assessed. Data from three independent experiments. (G) GFP fused to the N-terminal fragment of Sch9 (aa 1--390) localizes on the vacuole in wild-type cells but not in *vac7Δ* mutants. Vacuole membranes were visualized with FM 4-64. In wild-type or *vac7Δ* mutants, GFP fused to the full length (aa 1--824), N-terminus fragment (aa 1--390), or C-terminus fragment (aa 391--824) of Sch9 (green) was overexpressed. Vacuole membranes were visualized with FM 4-64.](1171fig3){#F3}

To extend our analysis, we examined the complementary situation, using the *FAB1^VLA^* mutant to generate elevated PI(3,5)P~2~. We found that concomitant with suppression of rapamycin sensitivity ([Figure 1B](#F1){ref-type="fig"}), expression of the hyperactive mutant in *vac7Δ* or *vac14Δ* yeast resulted in increased phosphorylation of Sch9^T570A^-HA~5~ ([Figure 3B](#F3){ref-type="fig"}; see 6% gel). In contrast, expression of an additional one or two copies of wild-type Fab1 had little effect on Sch9 phosphorylation in the *vac7∆* strain and showed partial suppression in *vac14∆* cells, in agreement with lack of suppression of rapamycin sensitivity. In addition, the degree of *FAB1^VLA^*-dependent phosphorylation of Sch9^T570A^-HA~5~ was lower in *vac7Δ* compared with the *vac14Δ* mutant. This parallels the levels of PI(3,5)P~2~, which are lower in the former mutant compared with the latter ([@B20]). Together these observations provide strong support for the hypothesis that PI(3,5)P~2~ is required for TORC1-dependent phosphorylation of Sch9.

In wild-type yeast, Sch9 is found both on the vacuole membrane and in the cytoplasm ([@B75]; [Figure 3C](#F3){ref-type="fig"}). Thus we tested whether PI(3,5)P~2~ is required for Sch9 recruitment to the vacuole. Note that the localization of GFP-Sch9 to the vacuole did not require active TORC1 ([Figure 3C](#F3){ref-type="fig"}); GFP-Sch9 localization in a *gtr1Δ* mutant was similar to that observed in the wild-type strain. However, the vacuolar localization of GFP-Sch9 was compromised in a *vac7Δ* mutant. Moreover, elevation of PI(3,5)P~2~ in the *vac7Δ* mutant by expression of hyperactive *FAB1^VLA^* restored the localization of Sch9 to the vacuole membrane ([Figure 3D](#F3){ref-type="fig"} and Supplemental Figure S3, B and C). These findings show that PI(3,5)P~2~ recruits the TORC1 substrate Sch9 to the vacuole and further suggest that Sch9 might directly bind this lipid.

To test this hypothesis, we generated a GST fusion protein of the first 400 amino acids of Sch9, which includes a C2 domain ([Figure 3E](#F3){ref-type="fig"}). C2 domains often bind specific phosphoinositide lipids ([@B46]). The Sch9 C2 domain--containing peptide bound PI(3,5)P~2~ with a dissociation constant of 11 ± 2 μM ([Figure 3, E and F](#F3){ref-type="fig"}, and [Table 1](#T1){ref-type="table"}). It is possible that Sch9 associates with other phosphoinositide lipids in vivo, including PI3P, which is also synthesized on endosomes. However, PI3P cannot recruit Sch9 in vivo: PI3P levels in a wild-type strain are 30-fold higher than PI(3,5)P~2~ levels ([@B20]), and in the *vac7Δ* mutant, the levels of PI3P are twofold higher than levels in a wild-type strain ([@B26]). Yet despite this high level of PI3P, Sch9 is not recruited to the vacuole. In addition, PI4P and PII4,5)P~2~ are not responsible for the recruitment of Sch9: in wild-type cells, PI4P and PI(4,5)P~2~ levels are ∼20-fold higher than that of PI(3,5)P~2~, and in the *vac7Δ* mutant the levels of PI4P and PI(4,5P~2~) remain unchanged ([@B26]). Together these data indicate that the association of Sch9 with the vacuole requires PI(3,5)P~2~ and that PI3P, PI4P, and PI(4,5)P~2~ cannot substitute for PI(3,5)P~2~.

We further tested and found that the N-terminal region of Sch9 (amino acids \[aa\] 1--390) is sufficient for the localization of Sch9 on the vacuole in vivo. Full-length Sch9-GFP (1--824), as well as the C2 domain--containing fragment, Sch9-GFP (1--390), localized on the vacuole membrane in the cytoplasm and the nucleus ([Figure 3G](#F3){ref-type="fig"}). However, in the *vac7Δ* mutant with low levels of PI(3,5)P~2~, the localization of Sch9-GFP (1--390) to the vacuole was defective ([Figure 3G](#F3){ref-type="fig"}). Together these data strongly suggest that association of Sch9 with the vacuole requires PI(3,5)P~2~, and that the N-terminal region of Sch9 contains the PI(3,5)P~2~-binding site.

PI(3,5)P~2~ is required for TORC1-dependent phosphorylation of Sch9 on the vacuole membrane
-------------------------------------------------------------------------------------------

That Sch9 associates with the vacuole membrane via PI(3,5)P~2~ suggests that PI(3,5)P~2~ serves as a platform for TORC1 and its target, Sch9. To address this hypothesis, we used an Sch9 C-terminal fragment (aa 709--824; cSch9), which contains all the TORC1 phosphorylation sites, S711, T723, S726, T737, S758, and S765 ([@B75]). We fused this fragment to either wild-type Vac8 or a mutant version, vac8-4; the vac8-4 protein is mutated at its myristoylation and palmitoylation sites (G2A, C4G, C5T, and C7S) and does not localize on the vacuole membrane ([@B77]). Accordingly, in wild-type yeast, Vac8-GFP-cSch9 localized on the vacuole membrane, whereas vac8-4--cSch9 was found in the cytoplasm ([Figure 4A](#F4){ref-type="fig"}). Similarly, in a membrane fractionation assay, Vac8 and Vac8-cSch9 were distributed in the P13 and P100 membrane fractions ([Figure 4B](#F4){ref-type="fig"}). In contrast, a large amount of vac8-4--cSch9 was also found in S13 and S100 cytosolic fractions ([Figure 4B](#F4){ref-type="fig"}). Of note, Vac8-cSch9 but not vac8-4--cSch9 was phosphorylated by TORC1 ([Figure 4C](#F4){ref-type="fig"}). These data suggest that the localization of Sch9 on the vacuole is required for its TORC1-dependent phosphorylation.

![PI(3,5)P~2~ is required for TORC1-dependent phosphorylation of Sch9 on the vacuole. (A) Vac8, but not vac8-4, fused to the C-terminal fragment of Sch9 (aa 709--824: cSch9) localizes on the vacuole in both wild-type cells and *vac7Δ* mutants. Vacuole membranes were visualized with FM 4-64. (B) In wild-type yeast, Vac8-cSch9 cofractionates with the P13 and P100 fractions, which include the vacuole. However, a large amount of vac8-4--cSch9 cofractionates with the S100, which corresponds to the cytosolic fraction. Cell lysates were centrifuged at 13,000 × *g* for 10 min at 4°C. Supernatant (S13) fractions and whole-cell lysates (W) were resuspended in the same volume of sample buffer, and the pellet (P13) fraction was resuspended in twice the volume of sample buffer. Then, S13 fractions were centrifuged at 100,000 × g for 30 min at 4°C. Supernatant (S100) fractions were resuspended in the same volume of sample buffer, and the pellet (P100) was resuspended in twice the volume of sample buffer. Loading controls for cellular fractionation were Vac7 and Vac8, which tightly localize on the vacuole membrane. Red asterisk, Vac7 protein. (C) Localization of cSh9 on the vacuole via PI(3,5)P~2~ is required for its TORC1-dependent phosphorylation. TORC1-dependent phosphorylation of Vac8-cSch9 or *vac8-4*-cSch9 assessed by mobility on 7% SDS--PAGE. Wild-type or *vac7Δ* yeast, with a plasmid expressing Vac8-cSch9-HA~5~ or vac8-4-cSch9-HA~5~, was grown in SC-His medium, and then a final concentration of 200 ng/ml rapamycin (+) was added to the cell culture. Cells were incubated for an additional 1 h. Lysates from 5 × 10^6^ cells with or without rapamycin treatment were incubated at 30°C for 1 h with (+) or without (--) 6000 U λ-phosphatase (New England Biolabs). As assessed by mobility on 7% SDS--PAGE, the degree of TORC1-dependent phosphorylation of Vac8-cSch9-HA~5~ was greatly diminished in both wild-type and *vac7Δ* mutant yeast with rapamycin treatment. Loading controls were Vac8- or vac8-4--cSch9-HA~5~ and Pgk1 run on 15% SDS--PAGE. Right, subset of analyses from left and middle repeated to allow side-by-side comparison of wild-type and vac7Δ strains. Of note, there was less phosphorylation of Vac8-cSch9 in *vac7Δ* than with a wild-type strain. This provides additional support for the hypothesis that PI(3,5)P~2~ plays additional roles beyond recruitment of Sch9.](1171fig4){#F4}

To examine this further, we expressed Vac8-cSch9 or *vac8-4*-cSch9 in a *vac7Δ* mutant. Similar to the wild-type strain, in the *vac7Δ* mutant, Vac8-cSch9 localized on the vacuole, but *vac8-4*-cSch9 was diffuse in the cytoplasm ([Figure 4A](#F4){ref-type="fig"}). Of importance, Vac8-cSch9 was phosphorylated by TORC1 in the *vac7Δ* mutant ([Figure 4C](#F4){ref-type="fig"}). These data suggest that PI(3,5)P~2~-dependent localization of Sch9 on the vacuole is required for its phosphorylation by TORC1. Together these findings strongly support the hypothesis that PI(3,5)P~2~ is critical for the localization Sch9 on the vacuole, where it is phosphorylated by TORC1.

Of note, when compared side by side, the degree of TORC1-dependent phosphorylation of Vac8-cSch9 in the *vac7Δ* mutant was less than in a wild-type strain ([Figure 4C](#F4){ref-type="fig"}, rightmost panel). This suggests that in addition to localization of the TORC1 target, PI(3,5)P~2~ on the vacuole has further roles in the positive regulation of TORC1.

PI(3,5)P~2~ is required for TORC1 phosphorylation of multiple substrates
------------------------------------------------------------------------

TORC1 functions in multiple pathways via phosphorylation of its targets and regulates cell growth. Because yeast mutants with defects in PI(3,5)P~2~ have pleiotropic defects, we tested whether PI(3,5)P~2~ is required for multiple TORC1-dependent pathways via regulation of TORC1 phosphorylation of additional targets.

Under nutrient-rich conditions, active TORC1 is required for inhibitory hyperphosphorylation of Npr1 ([@B72]), which allows ubiquitin-mediated endocytosis of selected plasma membrane transporters and their delivery for degradation in the vacuole ([@B51]). Of note, in the *vac7Δ* mutant, Npr1 was less phosphorylated than in a wild-type strain, and inhibition of TORC1 with rapamycin caused similar loss of phosphorylation of Npr1 in both strains ([Figure 5A](#F5){ref-type="fig"}).

![TORC1-dependent regulation of multiple pathways requires PI(3,5)P~2~. (A) Phosphorylation of Npr1-HA~3~ is greatly diminished in *vac7Δ* mutants. Wild-type or *vac7Δ* strains that express Npr1-HA~3~ were grown on YEPD; then rapamycin was added to a final concentration of 200 ng/ml. Cells were incubated for an additional 30 min. The degree of phosphorylation of Npr1 was assessed by migration during 6% SDS--PAGE. Loading control: Pgk1 run on 15% SDS--PAGE. (B) The *tor1Δ*, *fab1Δ*, and *vac7Δ* mutants with defects in TORC1 function are hypersensitive to canavanine. The indicated strains were grown to mid log phase in YEPD medium and then diluted onto SC-Arg plates in the presence or absence of 2 μg/ml canavanine, a sublethal dose for wild-type yeast. (C) Sensitivity of *vac7Δ* mutants to 1 μg/ml canavanine is rescued by elevation of PI(3,5)P~2~ levels. Wild-type cells with empty vector or the *vac7Δ* mutant with plasmids expressing mock, Fab1, or *FAB1^VLA^* were grown to mid log phase in SC-Ura medium and then diluted onto SC-Arg-Ura plates in the presence or absence of 1 μg/ml canavanine. (D) Phosphorylation of HA~3~-Atg13 is greatly diminished in *vac14Δ, vac7Δ, fab1Δ*, and *gtr1Δ* mutants. Wild-type, *vac14Δ*, *vac7Δ*, *fab1Δ*, or *gtr1Δ* strains with a plasmid expressing HA~3~-Atg13 were grown in SC-Leu medium, and then either a final concentration of 200 ng/ml rapamycin (+) or DMSO alone (--) was added to the cell culture. Cells were incubated for an additional 2 h. Lysates from 5 × 10^6^ cells from each strain were incubated at 30°C for 1 h with (+) or without (--) 6000 U of l-phosphatase (New England Biolabs). The degree of phosphorylation of Atg13 was assessed by migration in 6% SDS--PAGE. Loading control: Pgk1 run on 15% SDS--PAGE.](1171fig5){#F5}

TORC1-dependent phosphorylation of Npr1 releases its inhibitory block on the endocytosis of Can1, an arginine permease ([@B51]). Canavanine is a toxic analogue of arginine. Thus, under nutrient-rich conditions, mutants that do not have normal inhibition of Npr1 have excess Can1 on the plasma membrane and are hypersensitive to canavanine ([@B48]). The finding that less PI(3,5)P~2~ resulted in a defect in TORC1-dependent phosphorylation of Npr1 prompted us to test whether PI(3,5)P~2~ is required for TORC1-regulated inhibition of Npr1 to release its block on the endocytosis of Can1. We therefore analyzed canavanine sensitivity in *vac7Δ* and *fab1Δ* mutants. The *tor1Δ* mutant, as well as the *vac7Δ* and *fab1Δ* mutants, were hypersensitive to canavanine ([Figure 5B](#F5){ref-type="fig"}). *vac14Δ*, which is less defective in PI(3,5)P~2~ levels, was less sensitive than the *vac7Δ* mutant. To test further whether this defect was due to low levels of PI(3,5)P~2~, we expressed the hyperactive *FAB1^VLA^* mutant in the *vac7Δ* mutant and analyzed canavanine sensitivity. The increase in levels of PI(3,5)P~2~ by *FAB1^VLA^* suppressed the sensitivity to canavanine in the *vac7Δ* mutant ([Figure 5C](#F5){ref-type="fig"}). These data suggest that transport of Can1 from the plasma membrane via TORC1-dependent inhibitory phosphorylation of Npr1 requires PI(3,5)P~2~.

It is not known whether Npr1 is a direct target of TORC1. Thus, in addition to the direct target Sch9, we chose to examine Atg13, another well-characterized direct target of TORC1. Atg13 functions in the initiation of autophagy ([@B37]). Starvation or treatment of cells with rapamycin induces autophagy via inhibition of TORC1-inhibitory phosphorylation of Atg13.

We analyzed the degree of phosphorylation of Atg13 using mutants that have low levels of PI(3,5)P~2~. Atg13 is highly phosphorylated by TORC1 ([@B37]), and this phosphorylation is largely reversed by treatment with rapamycin or phosphatase ([Figure 5D](#F5){ref-type="fig"}). In the *gtr1∆* mutant with reduced TORC1 activity, Atg13 phosphorylation was decreased. Similarly, in *vac14Δ* or *vac7Δ* mutants with reduced levels of PI(3,5)P~2~, Atg13 was less phosphorylated ([Figure 5D](#F5){ref-type="fig"}).

Together these data suggest that PI(3,5)P~2~ is required for TORC1-dependent phosphorylation of multiple substrates and furthermore that through positive regulation of TORC1, PI(3,5)P~2~ regulates several pathways, including autophagy and nutrient-regulated endocytosis of Can1.

Autophagy is negatively regulated by PI(3,5)P~2~
------------------------------------------------

A previous study suggested that PI(3,5)P~2~ does not play a role in autophagy in yeast ([@B16]). However TORC1 phosphorylation of Atg13 is required to inhibit autophagy in nutrient-rich conditions. Moreover, TORC1-dependent activity of Sch9 also contributes to the inhibition of autophagy, independent of phosphorylation of Atg13 ([@B80]). Our findings that less PI(3,5)P~2~ caused defects in TORC1 phosphorylation of Atg13 and Sch9 led us to test whether lower levels of PI(3,5)P~2~ also resulted in a corresponding induction of autophagy under nutrient-rich conditions.

The autophagy pathway involves the sequestration of cytoplasm and/or organelles into autophagosomes, which fuse with the vacuole/lysosome. The breakdown of proteins and membranes in the vacuole provides new building blocks and energy for cellular renovation and homeostasis. We tested whether PI(3,5)P~2~ inhibits autophagy, using two common assays that monitor Atg8 behavior.

Atg8 is required for both autophagy and the cytoplasm-to-vacuole targeting (Cvt) pathway ([@B41]; [@B33]). Atg8 localizes on autophagosomes via its conjugation with phosphatidylethanolamine ([@B56]). Atg8 on the inner membrane of the autophagosome is delivered to the vacuole and is degraded there ([@B39]). In the case of GFP-Atg8, the GFP moiety is resistant to degradation and accumulates in the vacuole lumen. Thus production of free GFP from GFP-Atg8 can be used to monitor autophagy and the Cvt pathway either by microscopy or via Western blot analysis by probing for released GFP.

We expressed GFP-Atg8 in wild type or the *vac7Δ* mutant and quantified the induction of autophagy by microscopy. Wild-type yeast cells contained only single GFP-Atg8--positive puncta near the vacuole membrane under normal conditions, and the population of cells containing GFP puncta was \<20% ([Figure 6, A](#F6){ref-type="fig"} and [B](#F6){ref-type="fig"}). In addition, there was no detectable fluorescence signal within the vacuole lumen. On induction of autophagy using rapamycin treatment, GFP-Atg8 was targeted to the vacuole, free GFP was released, and the entire vacuole lumen was filled with GFP ([Figure 6A](#F6){ref-type="fig"}). During rapamycin treatment, the population of cells with GFP puncta or GFP-filled vacuoles increased to \>90% ([Figure 6B](#F6){ref-type="fig"}). In contrast, in the *vac7Δ* mutant, GFP puncta accumulated in the vacuole lumen even under basal conditions, and the population of cells with GFP puncta was \>70% ([Figure 6, A](#F6){ref-type="fig"} and [B](#F6){ref-type="fig"}). Note that the GFP-Atg8 in the vacuole lumen of *vac7∆* cells was present as puncta compared with the diffuse distribution seen in the lumen of wild-type cells. Of importance, the GFP puncta in the vacuole lumen were a result of the inappropriate induction of autophagy under nutrient-rich conditions. Atg1 plays a key role in the initiation and continuation of autophagy. When an *atg1Δ* mutant was treated with rapamycin, GFP-Atg8 was not transported to the vacuole lumen because autophagy was blocked (Supplemental Figure S4, A and B; [@B12]). Similarly, in a *vac7Δ atg1Δ* double mutant, whereas GFP-Atg8--positive puncta were observed in the cytoplasm near the vacuole membrane, these were not delivered to the vacuole either in basal conditions or during rapamycin treatment ([Figure 6, C](#F6){ref-type="fig"} and [D](#F6){ref-type="fig"}, and Supplemental Figure S4).

![PI(3,5)P~2~ regulates autophagy. PI(3,5)P~2~ is required both for inhibition of autophagy during vegetative growth and degradation of autophagic bodies. (A) Wild-type or *vac7Δ* strains with a plasmid expressing GFP-Atg8 were grown in SC-Ura medium. Rapamycin at a final concentration of 200 ng/ml was added, and cells were incubated for an additional 2 h. Vacuole membranes were visualized with FM 4-64. (B) Quantification of cells with GFP-Atg8 puncta or vacuoles filled with GFP or GFP-Atg8 from A. Three independent trials with \>100 cells counted/trial. Error bars in B represent SD of triplicate experiments. (C, D) *vac7Δ* or *atg1Δ vac7Δ* strains with a plasmid expressing GFP-Atg8 was grown in SC-Ura medium. Rapamycin at a final concentration of 200 ng/ml was added, and cells were incubated for an additional 2 h. Vacuole membranes were visualized with FM 4-64. (C) Quantification of cells with vacuoles filled with GFP or GFP-Atg8 from D. The data represent three independent trials with \>100 cells counted/trial. Error bars in C represent SD of triplicate experiments. (E). Quantification of the number of cells with Atg8 puncta or vacuoles filled with GFP or GFP-Atg8. Wild-type or *vac7Δ* strain with plasmids expressing GFP-Atg8 and mock, Vac7, Fab1, or *FAB1^VLA^* was grown in SC-Ura-Trp medium, and then a final concentration of 200 ng/ml rapamycin was added and cells were incubated for an additional 2 h. The data are an average from two trials with \>100 cells/trial. (F) Increasing PI(3,5)P~2~ by expression of the *FAB1^VLA^* mutant restores the defect in the degradation of GFP-Atg8. Wild-type or *vac7Δ* strain with plasmids expressing GFP-Atg8 and mock, Vac7, or *FAB1^VLA^* was grown in SC-Ura-Trp, and then a final concentration of 200 ng/ml rapamycin was added. Cells were incubated for an additional 4 h. Western blot was performed using anti-GFP antibody. Loading control: Pgk1.](1171fig6){#F6}

To further address whether PI(3,5)P~2~ is required for the inhibition of autophagy in nutrient-rich conditions, we expressed the hyperactive *FAB1^VLA^* mutant in *vac7Δ* cells and quantified the induction of autophagy by microscopy. Increasing the levels of PI(3,5)P~2~ by the *FAB1^VLA^* mutant or by expression of wild-type *VAC7* suppressed the accumulation of GFP puncta in the vacuole under basal conditions (Supplemental Figure S4C) and restored the number of cells without GFP puncta to wild-types levels in basal conditions ([Figure 6E](#F6){ref-type="fig"}). However, expression of Fab1 from a low-copy plasmid did not restore PI(3,5)P~2~ levels or suppress the inappropriate induction of autophagy under nutrient-rich conditions. Together these data suggest that PI(3,5)P~2~ is required for inhibition of autophagy under basal conditions.

In an independent test, we performed Western blot analysis for free GFP using whole yeast lysates from the cultures visualized in [Figure 6](#F6){ref-type="fig"}. In the *vac7Δ* mutant the degradation of GFP-Atg8 was inhibited under both nutrient-rich conditions and rapamycin treatment (Supplemental Figure S4D), consistent with the presence of GFP puncta in the vacuole lumen in the *vac7Δ* mutant. The presence of GFP puncta in the vacuole suggested that autophagosomes are transported into the vacuole but not degraded, resulting in accumulation of autophagic bodies. Consistent with this hypothesis, increasing the levels of PI(3,5)P~2~ by expressing the *FAB1^VLA^* mutant in the *vac7Δ* strain resulted in correct degradation of GFP-Atg8 in the vacuole lumen during the induction of autophagy ([Figure 6F](#F6){ref-type="fig"}).

The yeast vacuole is a weakly acidic compartment that contains a wide variety of hydrolases that are only active in this acidic environment. Furthermore, the pH gradient across the vacuole membrane establishes an electrochemical potential that is needed for the transport of various metabolites, including calcium and phosphate ions, establishing a unique milieu that is needed for optimal hydrolase activity. Accordingly, proper acidification is required for the degradation of autophagic bodies in the vacuole lumen but not for the formation or delivery of autophagosomes to the vacuole ([@B58]). Of importance, mutants with low or no PI(3,5)P~2~ do not have fully acidified vacuoles ([@B5], [@B6]; [@B18]). Together our studies indicate that the inhibition of autophagy by TORC1 is defective in mutants with low levels of PI(3,5)P~2~. In addition, we found that PI(3,5)P~2~ is required for the completion of autophagy. In the absence of PI(3,5)P~2~, autophagic bodies are not degraded in the vacuole lumen. Thus PI(3,5)P~2~ negatively regulates the induction of autophagy via positive regulation of TORC1 activity and positively functions in the resolution of autophagy through the degradation of autophagic bodies.

DISCUSSION
==========

The endosomal membrane lipid PI(3,5)P~2~ regulates multiple pathways. Pleiotropic defects observed in yeast, mice, and cultured cells caused by deficiencies in PI(3,5)P~2~ strongly suggest that many of the pathways regulated by PI(3,5)P~2~ have not yet been identified. Moreover, these pleiotropic phenotypes make it difficult to determine which individual pathways are directly regulated by this lipid. Identification of effector proteins provides a means to reveal processes that are directly modulated by PI(3,5)P~2~. Here we show that PI(3,5)P~2~ regulation of TORC1 is required for at least three TORC1-dependent pathways. Specifically, we show that 1) PI(3,5)P~2~ is required for the activation of TORC1 on the vacuole membrane; 2) a major substrate of TORC1, Sch9, associates with the vacuole membrane via PI(3,5)P~2~, and this association is required for TORC1-dependent phosphorylation of Sch9; and 3) PI(3,5)P~2~ plays a key role in additional TORC1-regulated pathways, including nutrient-dependent endocytosis of Can1 and inhibition of autophagy, via TORC1-dependent phosphorylation of Npr1 and Atg13, respectively. These studies expand our knowledge of pathways regulated by PI(3,5)P~2~ and show that via modulation of TORC1 function, PI(3,5)P~2~ is a key regulator of cellular response to nutrient status.

Regulation of TORC1 by PI(3,5)P~2~ on endosomal compartments
------------------------------------------------------------

Despite the importance of PI(3,5)P~2~ for modulation of TORC1, it is likely that PI(3,5)P~2~ is necessary but not sufficient for TORC1 activation. Note that hyperosmotic stress results in a 20-fold elevation of PI(3,5)P~2~ ([@B20]), yet this same treatment inhibits TORC1 phosphorylation of Sch9 ([@B75]). The inhibition of TORC1 during hyperosmotic stress occurs via as-yet-unidentified upstream regulators. This divergence in the effects of hyperosmotic shock on PI(3,5)P~2~ and TORC1 is consistent with the postulate that PI(3,5)P~2~ is not the sole upstream regulator of TORC1 function.

The precise mechanisms for PI(3,5)P~2~-dependent TORC1 activation remain to be determined. In yeast, TORC1 localizes on the vacuole with or without amino acid stimulation ([@B74]; [@B4]). In contrast, mTORC1 translocates onto the lysosome specifically during amino acid stimulation ([@B69]). The simple postulate that PI(3,5)P~2~ acts solely via recruitment of TORC1 to endosomes is unlikely because artificial recruitment of TORC1 to the vacuole in the absence of PI(3,5)P~2~ only partially restores TORC1 function ([Figure 2](#F2){ref-type="fig"}). Our findings, as well as others, suggest three ways that PI(3,5)P~2~ may play roles in the activation of TORC1.

First, amino acids play a major role in the regulation of TORC1. Thus PI(3,5)P~2~ may be involved in sensing amino acids. The vacuole/lysosome is a major reservoir for amino acids ([@B55]), which are released as needed during vegetative growth. In mammals, amino acids stored in the lysosome are detected by the lysosomal V-ATPase, which in turn activates TORC1 ([@B84]). Of note, yeast mutants with defects in PI(3,5)P~2~ have less-acidified vacuoles and may have defects in V-ATPase activity ([@B6]). Thus PI(3,5)P~2~ may indirectly activate TORC1 via direct activation of the V-ATPase. However, this is unlikely to be the sole role of PI(3,5)P~2~ in TORC1 function. Both Kog1 and Sch9 interact directly with PI(3,5)P~2~. Moreover, PI(3,5)P~2~ is required to recruit Sch9 to the vacuole, where it is phosphorylated by TORC1.

Second, PI(3,5)P~2~ may directly activate TORC1. The essential TORC1 subunit Raptor functions as a scaffold for the TORC1 complex ([@B29]; [@B40]; [@B62]; [@B70]; [@B79]), and yeast Kog1 likely serves similar roles. Of note, Kog1 (Supplemental Figure S1) and its mammalian homologue, Raptor ([@B8]), directly bind PI(3,5)P~2~ in vitro. Thus PI(3,5)P~2~ may activate TORC1 through direct interaction with Kog1/Raptor, which may modulate the structure of TORC1. However, integrity of the TORC1 complex does not appear to be grossly affected by loss of PI(3,5)P~2~; Kog1 interaction with Tor1 still occurs in a *vac7Δ* mutant (Supplemental Figure S2).

Third, a membrane subdomain that includes PI(3,5)P~2~ may exist on the vacuole and serve as a platform for TORC1, its substrates, and regulators, including the EGO complex. Recruitment of the TORC1 substrate Sch9 to the vacuole requires PI(3,5)P~2~. Moreover, in a global study, Ego3, a component of the EGO complex, was shown to bind phosphorylated phosphatidylinositol lipids ([@B82]).

TORC1-dependent phosphorylation occurs on vacuole/lysosome membranes
--------------------------------------------------------------------

That PI(3,5)P~2~-dependent localization of Sch9 on the vacuole is required for TORC1-dependent phosphorylation of Sch9 ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}) makes it tempting to speculate that TORC1 phosphorylation of multiple targets may require their recruitment to the vacuole/lysosome by PI(3,5)P~2~. In mammals, S6K and eIF4E-binding protein 1 ([@B9]; [@B30]; [@B10]; [@B34]), the transcription factor EB (TFEB; [@B73]), lipin-1 ([@B65]), and Atg13 and Ulk1 ([@B32]), and in yeast, Sch9, Atg13 ([@B37]), Sfp1 ([@B47]), and Gln3 ([@B3]), are direct targets of TORC1. With the exception of TFEB and Sch9, the location where these targets are phosphorylated by TORC1 is not known. mTORC1-dependent phosphorylation of TFEB occurs on the lysosome and regulates the translocation of TFEB to the nucleus during lysosomal stress or amino acid stimulation ([@B64]; [@B73]). The activation of Rag GTPase by the V-ATPase ([@B73]) and the association of active Rags with TFEB ([@B52]) are required for translocation of TFEB to the lysosome. Whether PI(3,5)P~2~ is required for TORC1 phosphorylation of TFEB or other targets has not been tested. Perhaps TFEB or other substrates, including S6K, target to the lysosome/vacuole membrane via PI(3,5)P~2~ and are thereby brought to TORC1 via PI(3,5)P~2~ signaling ([Figure 7](#F7){ref-type="fig"}).

![PI(3,5)P~2~ is a critical upstream regulator of TORC1. (A) PI(3,5)P~2~-dependent activation of TORC1 and recruitment of substrates to the vacuole membrane. Kog1, a subunit of TORC1, and the TORC1 substrate, Sch9, are downstream effectors of PI(3,5)P~2~. PI(3,5)P~2~ recruits Sch9 and likely additional TORC1 targets to the vacuole, where their TORC1-dependent phosphorylation occurs. (B) PI(3,5)P~2~ is required for TORC1-dependent phosphorylation of multiple substrates and TORC1-dependent inhibition of autophagy, as well as regulation of nutrient-dependent endocytosis. TORC1-dependent phosphorylation of each substrate tested, Sch9, Npr1, and Atg13, requires PI(3,5)P~2~, which suggests that phosphorylation of these substrates occurs on the vacuole. In addition, PI(3,5)P~2~-mediated TORC1-dependent phosphorylation of Npr1 or Atg13 is required to release Npr1-dependent inhibition of Can1 endocytosis and TORC1-dependent inhibition of autophagy, respectively. Note that in addition to regulation of TORC1, PI(3,5)P~2~ modulates pathways that are independent of TORC1 signaling.](1171fig7){#F7}

Roles for PI(3,5)P~2~ in autophagy
----------------------------------

Atg13 is a direct target of TORC1 and is hyperphosphorylated under nutrient-rich conditions, which inhibits autophagy ([@B37]). Although it had been reported that in yeast PI(3,5)P~2~ is not involved autophagy ([@B16]), we found that PI(3,5)P~2~ is required for TORC1-dependent inhibition of autophagy ([Figures 6](#F6){ref-type="fig"} and Supplemental Figure S4) via TORC1 phosphorylation of Atg13 ([Figure 5D](#F5){ref-type="fig"}). These findings make it tempting to speculate that Atg13 is an effector of PI(3,5)P~2~. Atg13, as well as additional proteins, play key roles in the initiation of autophagy and, as part of the initiation, are recruited to the phagophore assembly site (reviewed in [@B59]). PI(3,5)P~2~ may be required for recruitment of Atg13 to the phagophore assembly site via TORC1-dependent phosphorylation of Atg13.

That PI(3,5)P~2~ is required for TORC1 inhibition of autophagy raises the possibility that Atg18, which plays a role in the formation of autophagosomes ([@B63]; [@B57]), may also serve a second role in autophagy. Atg18, independent of its role in forming autophagosomes, is a negative regulator of PI(3,5)P~2~ synthesis ([@B16]). Through two adjacent sites, Atg18 tightly binds both PI3P and PI(3,5)P~2~ ([@B16]; [@B2]; [@B43]; [@B78]). These lipid-binding sites on Atg18 are required for Atg18 localization on the vacuole, both for the autophagy pathway ([@B63]; [@B57]) and for negative regulation of the synthesis of PI(3,5)P~2~ ([@B16]; [@B22]). Perhaps via inhibition of PI(3,5)P~2~ synthesis, Atg18 promotes the inhibition of TORC1 and the subsequent activation of autophagy.

PI(3,5)P~2~ also plays a TORC1-independent role in autophagy. The absence of PI(3,5)P~2~ causes defects in the degradation of autophagic bodies ([Figure 6](#F6){ref-type="fig"} and Supplemental Figure S4), which are likely due to defects in the acidification of the vacuole ([@B5], [@B6]; [@B58]). These findings show that there are both TORC1-dependent and TORC1-independent roles for PI(3,5)P~2~ in autophagy. Moreover, in the absence of PI(3,5)P~2~, the induction of autophagy during nutrient-rich conditions is likely further exacerbated by PI(3,5)P~2~-related defects in the degradation of autophagic bodies.

These roles for PI(3,5)P~2~ in the inhibition of autophagy and the resolution of autophagic bodies are likely conserved. Autophagy is important for neural function and neonatal survival in mice ([@B44]; [@B28]; [@B23]). Similarly, mice deficient in the synthesis of PI(3,5)P~2~ show defects in the nervous system and early lethality ([@B81]; [@B83]). These similarities are consistent with a link between PI(3,5)P~2~ and autophagy in all metazoans. Indeed, defects in Fab1/PIKfyve function cause autophagic dysfunction in mammals ([@B35]; [@B15]; [@B24]; [@B53]), *Caenorhabditis elegans* ([@B61]), and *Drosophila* ([@B68]). Similar to yeast, defects in PI(3,5)P~2~ production in mammalian cells result in the loss of nutrient-dependent inhibition of autophagy ([@B35]; [@B53]). Thus the requirement for PI(3,5)P~2~-dependent activation of TORC1 for inhibition of autophagy is likely conserved. The TORC1-dependent and independent roles for PI(3,5)P~2~ described here join a growing list of pathways modulated by PI(3,5)P~2~. The pleiotropic defects in yeast, cultured mammalian cells, and mice predict that PI(3,5)P~2~ likely has multiple additional roles in endosomal physiology.

MATERIALS AND METHODS
=====================

Strains and media
-----------------

Yeast strains and plasmids are listed in the Supplemental Experimental Procedures. Yeast were grown in yeast extract/peptone/dextrose (YEPD) or synthetic minimal medium without selective amino acid(s) at 24°C. Construction of plasmids and strains is described in the Supplemental Experimental Procedures.

Generation of functional Tor1-3xGFP and Kog1-3xGFP
--------------------------------------------------

To generate functional Tor1-3xGFP, we expressed Tor1 with internally integrated 3xGFP at amino acid D330, a site that does not impair Tor1 localization or function ([@B74]). This construct was expressed as the sole copy of *TOR1* from the *TOR1* endogenous locus. For Kog1, the 3xGFP tag was placed at the C-terminus of Kog1. Kog1-3xGFP was expressed as the sole copy of *KOG1* from the endogenous locus.

Fluorescence microscopy
-----------------------

Mid--log phase cells were labeled with FM 4-64 ([@B76]). Images were acquired using the DeltaVision RT Restoration Microscopy System (Applied Precision, Issaquah, WA).

Rapamycin sensitivity
---------------------

Cells were grown as indicated in YEPD or selective media to mid log phase. Cells were collected and resuspended in media, and 10-fold serial dilutions from 0.1 OD/ml were performed. Cells were transferred to YEPD or selective media plates containing dimethyl sulfoxide (DMSO; control) and the indicated concentrations of rapamycin. Cells were incubated at 24°C for 2--7 d or 37°C for 2--7 d. Images were obtained every day starting at day 2.

Protein purification
--------------------

Proteins were expressed in *E. coli* BL21 star (DE3) pRARE. Cells were grown in Luria broth with 0.05 mg/ml ampicillin and 0.025 mg/ml spectinomycin at 37°C to an OD~600~ of 0.3. After 18 h of induction with 0.2 mM isopropyl-β-[d]{.smallcaps}-thiogalactoside at 16°C, cells were harvested. Cells were sonicated in lysis buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM dithiothreitol \[DTT\]). Proteins were purified with glutathione Sepharose resin (GE Healthcare, Little Chalfont, Buckinghamshire, England), concentrated by spin filtration using an Ultrafree-4 centrifugal filter 50K or 30K membrane (Millipore, Darmstadt, Germany), and dialyzed in Biacore buffer (25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 150 mM NaCl, 1 mM DTT).

Western blot
------------

Log-phase cells were lysed ([@B21]), and the lysates separated by SDS--PAGE and transferred to nitrocellulose. Antibody dilutions were anti-Pgk1 (Invitrogen, Grand Island, NY), 1:10,000; anti-hemagglutinin (Covance, Princeton, NJ), 1:3000; and anti-GFP (Roche, Basel, Switzerland), 1:500.

Surface plasmon resonance analysis
----------------------------------

Surface plasmon resonance analysis was performed as described previously ([@B16]; [@B60]). GST-Atg18 (PI(3,5)P~2~) served as a positive control ([@B16]), and GST was a negative control. Proteins were used within 24 h of cell lysis, and lipid surfaces were used within 8 h of generation. Affinity was measured using sensor surfaces containing di-oleyl-phosphatidylcholine liposomes doped with PI(3,5)P~2~ at a molar ratio of 97:3. In an initial experiment, no binding was detected between GST-Sch9 or GST-Kog1 and the PI(3,5)P~2~ surface. To increase sensitivity, the molar ratio of PI(3,5)P~2~ was increased to 22:3. Binding was measured by flowing protein samples over the sensor surface. Lipids (Eschelon) were bound to sensor chips, L1 (Biacore, GE Healthcare). Four sensors were available for each run. The first and second sensors contained only phosphatidylcholine (PC). The subsequent two sensors contained PC:PI(3,5)P~2.~ Two sensors were dedicated to PC:PI(3,5)P~2~ in order to obtain more accurate binding constants. Phosphoinositides:PC were present at a molar ratio of 22:3. Response to PC alone was subtracted from the responses detected from the phosphoinositide-containing chips. Binding data are presented at the indicated protein concentration injected. The *K*~d~ values and maximum binding (*R*~max~) were calculated by using Prism (GraphPad). Data were fitted to the equation where *Y* is total binding, *X* is the protein concentration, *B*~max~ is the maximum specific binding in the same units as *Y*, and *K*~d~ is the equilibrium binding constant in the same units as *X*. Background is the amount of nonspecific binding with no added protein.
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